Drug intelligence / Profile preview

XB064

Development stage: Preclinical
Lead developer: Exelixis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

XB064 is a preclinical-stage monoclonal antibody targeting ILT2 (also known as LILRB1), developed by Exelixis. It is being investigated as an immunotherapy for cancer, specifically neoplasms. The drug acts as an inhibitor of the leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1/ILT2), which is thought to play a role in immune evasion by tumors. By blocking this inhibitory receptor on immune cells, XB064 aims to enhance anti-tumor immune responses[1][4][5].

Other names: XB-064XB064XB 064

Targets

LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)

Beyond the preview

Go deeper on XB064.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XB064.

Explore the full profile